Search - tctmd.com

Displaying 1 - 20 of 51

Sort: Relevancy | Date

Presentation TCT India 2025

DAPT in STEMI – Do We Have Clarity on Drug, Dose and Duration?

Presenter: Rishi Sethi

July 26, 2025

Presentation EuroPCR 2024

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Presenter: Ling Tao

May 15, 2024

Presentation ACC 2024

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Presenter: Gregg W Stone

April 07, 2024

Presentation JIM 2018

Clinical Case: Management of Long-Term DAPT

Presenter: Ugo Limbruno

February 23, 2018

Presentation TTT 2018

Prolonged DAPT should be Standard of Care Post PCI?

Presenter: Tan Huay Cheem

January 14, 2018

Presentation Cardiovascular Interventions 2017

DAPT Duration After Stenting: An Updated Appraisal

Presenter: Dean J. Kereiakes

November 09, 2017

Presentation

Lesion Complexity and Outcomes of Extended DAPT After PCI

October 23, 2017

Presentation SIF 2017

PCI Pharmacology in 2017: Understanding the Essentials

Presenter: MIchael A. Kutcher

March 09, 2017

Presentation

Efficacy and Safety of DAPT After Complex PCI

Presenter: Gennaro Giustino

September 01, 2016

Presentation

Impact Of Gender on 2-Year Clinical Outcomes in Patients Treated With 6- or 24-Month DAPT

Presenter: Giuseppe Gargiulo

August 19, 2016

Presentation

Use of DAPT and Patient Outcomes in Those Undergoing PCI: The ROCKET AF Trial

Presenter: Matthew W. Sherwood

August 16, 2016

Presentation CCVVC 2016

Timing of DAPT Interruption and DES Thrombosis

Presenter: Usman Baber

June 16, 2016

Presentation CCVVC 2016

Novel Anti-thrombotics in Patients with Peripheral Artery Disease

Presenter: Marc P. Bonaca

June 15, 2016

Presentation EuroPCR 2016

Effect of DAPT Termination at 12 Months on Very Late scaffold thrombosis in regular clinical practice: Data of a regional collaboration

Presenter: Robert-Jan van Geuns

May 18, 2016

Presentation Fellows 2016

Case 1: Dilemmas in DAPT and PCI Pharmacology

Presenter: Allen Jeremias

April 15, 2016

Presentation JIM 2016

DES safety and DAPT: The Ultimaster DES

Presenter: Corrado Tamburino

February 10, 2016

Presentation JIM 2016

BioFreedom DCS With 1-Month DAPT: The New Standard For High Bleeding Risk Patients

Presenter: Antonio L. Bartorelli

February 10, 2016

Presentation

Outcomes of Patients With Acute MI Undergoing PCI Receiving an Oral Anticoagulant and DAPT

Presenter: Larry R. Jackson

December 21, 2015

Presentation

Left Main or Proximal LAD (LM-pLAD) Coronary Artery Disease Location Identifies High-Risk Pts Deriving Potentially Greater Benefit From Prolonged Dual Antiplatelet Therapy (DAPT)

Presenter: F. Costa

August 21, 2015

Presentation Fellows 2015

Case 2

Presenter: Roxana Mehran, David J. Cohen, Kevin J. Croce

May 15, 2015

Advertisement

DAPT in STEMI – Do We Have Clarity on Drug, Dose and Duration?

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Clinical Case: Management of Long-Term DAPT

Prolonged DAPT should be Standard of Care Post PCI?

DAPT Duration After Stenting: An Updated Appraisal

Lesion Complexity and Outcomes of Extended DAPT After PCI

PCI Pharmacology in 2017: Understanding the Essentials

Efficacy and Safety of DAPT After Complex PCI

Impact Of Gender on 2-Year Clinical Outcomes in Patients Treated With 6- or 24-Month DAPT

Use of DAPT and Patient Outcomes in Those Undergoing PCI: The ROCKET AF Trial

Timing of DAPT Interruption and DES Thrombosis

Novel Anti-thrombotics in Patients with Peripheral Artery Disease

Effect of DAPT Termination at 12 Months on Very Late scaffold thrombosis in regular clinical practice: Data of a regional collaboration

Case 1: Dilemmas in DAPT and PCI Pharmacology

DES safety and DAPT: The Ultimaster DES

BioFreedom DCS With 1-Month DAPT: The New Standard For High Bleeding Risk Patients

Outcomes of Patients With Acute MI Undergoing PCI Receiving an Oral Anticoagulant and DAPT

Left Main or Proximal LAD (LM-pLAD) Coronary Artery Disease Location Identifies High-Risk Pts Deriving Potentially Greater Benefit From Prolonged Dual Antiplatelet Therapy (DAPT)

Case 2

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content